



**AUXELLECE**  
**Health Corporation**

## **Auxellence Announces 2<sup>nd</sup> Stage of Commercial Pilot of the TULIP™ Health System and Corporate Update**

VANCOUVER, BC, Wednesday, December 23, 2015 – Auxellence Health Corporation (CSE:AID, OTCQB: AXHLF) is pleased to announce that it is ready to begin the 2<sup>nd</sup> Stage of its Commercial Pilot of the Tulip(TM) Theranostic (Therapeutic & Diagnostic) Health System of 1,000 units to be deployed subject to funding.

With this next stage of the company's development, Management expects to provide more frequent and engaging shareholder communications in the near future; and in the meantime would like to extend "Seasons Greetings" to everyone.

Management would also like to provide the following corporate update:

### **2015 Corporate Update**

- Auxellence has been working diligently on the Pioneer Edition of TULIP(TM) over the past year and is very pleased with the results. .
- The company completed the Plan of Arrangement prior to the company's fiscal year end and has been waiting for the remaining companies to complete the share push outs to issue final details clarifying any remaining portions of the transaction in a joint press release.
- As previously disclosed in its monthly reports, the company had terminated the engagement with Mr. Michael Lerner, principle of Lerner Finance Inc., and his private Ontario Corporation. The company wishes to thank Mr. Lerner and his company for his efforts.
- The company is no longer actively working with either Intrinsic Venture Corp. or Clearview Capital Inc. as their engagements have been either terminated or dissolved. The company is appreciative of their efforts.
- The Issuer remains focused on its Canadian roll-out, as no financing has been secured by the interested party for the non-exclusive USA rights distribution agreement. As a result, there has been no new agreement signed and the Issuer retains the right to explore this opportunity again in the future.



**AUXELLECE**

**Health Corporation**

- Auxellence has built up and has been relying on its goodwill with its primary medical device manufacturer and commercial operator, and continues to work with them despite a funding deficit of its primary General Service Agreement.
- Auxellence had acquired the intellectual property underlying the company's interactive health care system (subject to certain terms and conditions). – The company continues to work towards satisfying any of the remaining terms of the agreement.
- The company was previously negotiating with an ECG based medical device firm for the Canadian rights of their product to be incorporated into the issuer's healthcare platform for nutraceutical and cosmeceutical skin health. The company had felt that there was a meeting of the minds for the transaction, subject to financing; which has not yet occurred. As a result, this has not proceeded and has now been put aside and will be revisited when market conditions or funding for such a project improves.
- The company continues to review opportunities in the medical monitoring, diagnostics and therapeutics fields, and hopes to be able to bring significant value propositions to potential customers and shareholders. Management expects to provide further updates in the near future and in the meantime continues to work on behalf of the shareholders.

**Contact:**

Sydney Au, CEO

Auxellence Health Corporation

Email: [ceo@auxellence.com](mailto:ceo@auxellence.com)

Phone: (604) 780-3311

Website: <http://www.auxellence.com>

CSE Micro-site: <http://www.cnsx.ca/CNSX/Securities/Technology/Auxellence-Health-Corporation.aspx>

**About Tulip™**

TULIP™ is a medical device cleared for sales in Canada and Europe as a blood pressure monitor with interactive protocols. The device enables physiologically interactive health apps useful in testing, tracking, and treating common health conditions. The online system is aimed primarily at “practicing patients” interested in normalizing blood pressure, blood glucose, and body weight. Session schedules, measurement procedures, and conditioning protocols are prescribed automatically by the system from extemporaneous data acquired from the user.

**About Auxellence Health Corporation (CSE: AID, OTCQB: AXHLF)**

Auxellence is a technology company engaged in the provision of medical monitoring, diagnostics, therapeutics and biomedical online services for common health problems. The company offers an extensive platform for physiologically interactive computing supporting



**AUXELLE**

**Health Corporation**

therapeutic-diagnostic (theranostic) devices, expert systems, and recommender applications for personal health management. The initial focus is on weight management and skin conditions.

**Disclaimer for Forward-Looking Information**

Statements in this press release regarding the Company which are not historical facts are “forward-looking statements” that involve risks and uncertainties. Such information can generally be identified by the use of forwarding-looking wording such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intend”, “believe” and “continue” or the negative thereof or similar variations. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated in such statements due to factors. The Company does not intend to update any changes to such statements, except as required by law. Although Management believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. We seek safe harbour.

THIS PRESS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES